...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >An Update of Recent Trials with Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes
【24h】

An Update of Recent Trials with Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes

机译：维拉格列汀，二肽肽酶-4抑制剂治疗2型糖尿病的最新试验的更新。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To review the clinical efficacy and tolerability of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, for the treatment of type 2 diabetes, based on recent Phase 3 trials. Data Sources: Primary literature and review articles were obtained via a MEDLINE search (2005-November 2007) using the search terms diabetes, vildagliptin, and LAF-237. Additional data from abstracts presented at clinical meetings were included when appropriate. Study Selection: Nine double-blind, randomized, multicenter, parallel-group trials and vildagliptin studies were identified and reviewed. Data Synthesis: Vildagliptin, a selective DPP-4 inhibitor, has been shown to produce clinically significant reductions in hemoglobin A_(1c) (A1C) levels when used as monotherapy (0.6-1%) or in combination with other glucose-lowering agents (mean decrease 0.7%). Phase 3 trials indicated a 24- to 52-week sustained effect on reduction of blood glucose in patients with type 2 diabetes. The primary endpoint for all trials was change from baseline A1C. In the intent-to-treat population, baseline A1C was compared with end-of-study A1C. More than 2,500 patients with type 2 diabetes enrolled in monotherapy trials; an additional 2,119 participated in combination therapy trials. Males outnumbered females, and all groups included obese patients. The most common adverse effects reported were nasopharyngiris, headache, and dizziness. Vildagliptin was weight-neutral and produced a rate of hypoglycemia similar to that of placebo. Conclusions: Vildagliptin appears to be a promising agent for the management of type 2 diabetes.
机译：目的：基于最近的3期临床试验，综述二肽基肽酶4（DPP-4）抑制剂维格列汀治疗2型糖尿病的临床疗效和耐受性。数据来源：主要文献和评论文章是通过MEDLINE搜索（2005年11月至2007年11月）使用搜索词糖尿病，维达列汀和LAF-237获得的。在适当的时候，还包括在临床会议上发表的摘要的其他数据。研究选择：鉴定并审查了9项双盲，随机，多中心，平行组试验和维格列汀研究。数据综合：维尔达列汀，一种选择性DPP-4抑制剂，已显示在单药治疗（0.6-1％）或与其他降糖药联合使用时，会产生血红蛋白A_（1c）（A1C）水平的临床显着降低（平均下降0.7％）。 3期试验表明，对2型糖尿病患者的血糖降低具有24至52周的持续作用。所有试验的主要终点是基线A1C的变化。在意向性治疗人群中，将基线A1C与研究结束时的A1C进行了比较。超过2500名2型糖尿病患者参加了单药治疗试验;另外2119人参加了联合疗法试验。男性多于女性，并且所有组均包括肥胖患者。报告的最常见不良反应是鼻咽，头痛和头晕。维格列汀是体重中性的，产生的低血糖发生率与安慰剂相似。结论：维格列汀似乎是治疗2型糖尿病的有前途的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号